Our Latest Research Findings

Our Latest Research Findings

2017

Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women
Moderate-severe vasomotor symptoms are associated with moderate-severe depressive symptoms
Vasomotor symptoms are associated with depressive symptoms in community-dwelling older women
Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review
Hypoactive sexual desire dysfunction in community-dwelling older women

2016

Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial
Hypoactive sexual desire dysfunction in community-dwelling older women
Symptomatic pelvic floor disorders in community-dwelling older Australian women
Androgens and Female Sexual Function and Dysfunction-Findings from the Fourth International Consultation of Sexual Medicine
Menopausal vasomotor symptoms are assicated with poor self-assessed work ability
Awareness of breast cancer barriers to breast screening uptake in Bangladesh: A population based survey
Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey
Hormones and female sexual dysfunction: Beyong estrogens and androgrens-Findings from the Fourth International Consultation on Sexual Medicine
Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline
Prevalence of, and risk factors for, symptomatic pelvic organ prolapse in Rural Bangladesh: a cross-sectional survey study

2015

Metformin for overweight women at midlife: a double-blind, randomized, controlled trial
Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife
Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years
Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40–65 years
Bangladesh Midlife Women’s Health Study (BMWHS): Methods, challenges and experiences
Lack of Understanding of Cervical Cancer and Screening Is the Leading Barrier to Screening Uptake in Women at Midlife in Bangladesh: Population-Based Cross-Sectional Survey
Vasomotor and sexual symptoms in older Australian women: a cross-sectional study
Targeted assessment of fracture risk in women at midlife

2014

Prevalence of menopausal symptoms in Australian women at midlife: a systemic review.
Application site affects the pharmacokinetics of topical testosterone applied to the axillae compared with the inner arm
Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis.
A  comparison of the characteristics, treatment and outcome after 5 years,  of Australian women aged 70 + with those aged < 70 years at the time  of diagnosis of breast cancer.
Persistent  breast pain 5 years after treatment of invasive breast cancer is  largely unexplained by factors associated with treatment
Testosterone  improves antidepressant- emergent loss of libido in women: findings  from a randomized, double-blind, placebo-controlled trial.
Intended follow-up of women with breast cancer at low risk of recurrence and at least 5 years from diagnosis
A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania.
Women's expectations and experiences of hormone treatment for sexual dysfunction.
Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy.

2013

Transdermal Testosterone Therapy Improves Selective Serotonin Reuptake Inhibitor-associated Sexual Dysfunction in Women
Change to Either a Non-Androgenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction
The Effects of Testosterone on Brain Function in Postmenopausal women
Do Hormones Influence Cholesterol Levels after Menopause?
Lymphedema: experience of a cohort of women with breast cancer followed for 4 years after diagnosis in Victoria, Australia
Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis
Intended followup of women with breast cancer at low risk of recurrence and at least 5 years from diagnosis
Pregnancy-associated breast cancer and pregnancy following treatment for breast cancer, in a cohort of women from Victoria, Australia, with a first diagnosis of invasive breast cancer
Persistent breast pain 5 years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment

ARCHIVED RESULTS 2010 - 2012